O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation

  title={O-GlcNAcylation plays a role in tumor recurrence of hepatocellular carcinoma following liver transplantation},
  author={Qian-qian Zhu and Lin Zhou and Zhe Yang and Ming-chun Lai and Haiyang Xie and Liming Wu and Chun-Yang Xing and Feng Zhang and Shusen Zheng},
  journal={Medical Oncology},
O-linked-ß-N-acetylglucosamine (O-GlcNAc) modification is a crucial post-translational modification. The enzymes responsible for the addition and removal of O-GlcNAc have been identified as O-GlcNAc transferase (OGT) and O-GlcNAcase (OGA). In this study, O-GlcNAcylation level was examined in forty hepatocellular carcinoma (HCC) tissues of patients who underwent liver transplantation (LT) and ten healthy liver tissues by immunohistochemistry analysis. We also examined the expression of OGT and… 
Overexpression of O-GlcNAc-transferase associates with aggressiveness of mass-forming cholangiocarcinoma.
It is shown for the first time that O-GlcNAcylation is increased in CCA tissues and is associated with a poor patient outcome and the OGT expression level could be a useful prognostic indicator and inhibition of O- glucosaminidase might be a therapeutic target for CCA.
O-GlcNAcylation: A New Cancer Hallmark?
Increasing number of evidences point out the central involvement of O-GlcNAcylation in tumorigenesis, justifying the attention received as a potential new approach for cancer treatment.
Aberrant O-GlcNAc-modified proteins expressed in primary colorectal cancer.
The results indicate that aberrant O- GlcNAcylation of proteins is associated with colorectal cancer and that identification of O-GlcNAc-modified proteins may provide novel biomarkers of cancer.
O-GlcNAcylation is increased in prostate cancer tissues and enhances malignancy of prostate cancer cells.
Overall, these findings indicated that O-GlcNAcylation is increased in prostate, but not in liver and pancreatic cancer tissues, and that O/N-acetylglucosamine moiety can enhance the malignancy of prostate cancer cells.
Elevated O-GlcNAcylation promotes gastric cancer cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling
It is reported that hyper-O-GlcNAcylation significantly promotes GC cells proliferation by modulating cell cycle related proteins and ERK 1/2 signaling, suggesting that inhibition of OGT may be a potential novel therapeutic target of GC.
Mechanistic insights of O-GlcNAcylation that promote progression of cholangiocarcinoma cells via nuclear translocation of NF-κB
The significance of O-GlcNAcylation in controlling the metastatic ability of CCA cells is indicated and its products may be new targets for treatment of metastatic CCA.
Immunohistochemical Study of O-GlcNAcylation in Human Skin Tumors
The results suggest that O-GlcNAcylation of proteins may play an important role in the development of human skin tumors.
O-linked N-acetylglucosamine transferase (OGT) is overexpressed and promotes O-linked protein glycosylation in esophageal squamous cell carcinoma
It is found that the expression of OGT was higher in esophageal squamous cell carcinoma samples compared to the normal tissues, and O-GlcNAcylation may play an important role in esphageal Squamous Cell carcinoma.
Essential role of O-GlcNAcylation in stabilization of oncogenic factors.


O-GlcNAcylation is a novel regulator of lung and colon cancer malignancy.
GlcNAcylation plays an essential role in breast cancer metastasis.
It is shown that GlcNAcylation enhances the migration/invasion of breast cancer cells in vitro and lung metastasis in vivo and suggests that it might be a potential target for the diagnosis and therapy of Breast cancer.
Modulation of transcription factor function by O-GlcNAc modification.
O-GlcNAc modification: why so intimately associated with phosphorylation?
It is hypothesize that phosphorylation may be a requisite for O-GlcNAc modification and tyrosine phosphorylated plays a role in the interplay between O- GlcNAC modification and serine/threonineosphorylation in proteins.
Nutrient sensor O-GlcNAc transferase regulates breast cancer tumorigenesis through targeting of the oncogenic transcription factor FoxM1
Findings identify O-GlcNAc as a novel mechanism through which alterations in glucose metabolism regulate cancer growth and invasion and suggest that OGT may represent novel therapeutic targets for breast cancer.
O-GlcNAcylation regulates phosphorylation of tau: a mechanism involved in Alzheimer's disease.
It is demonstrated that human brain tau was modified by O-GlcNAcylation, a type of protein O-glycosylation by which the monosaccharide beta-N-acetylglucosamine (Glc NAc) attaches to serine/threonine residues via an O-linked glycosidic bond, which reveals a mechanism of regulation of tau phosphorylation.
Phosphoinositide signalling links O-GlcNAc transferase to insulin resistance
It is shown that O-GlcNAc transferase (OGT) harbours a previously unrecognized type of phosphoinositide-binding domain, which underscores the contribution of this modification to the aetiology of insulin resistance and type 2 diabetes.
Predictive Value of Expression and Promoter Hypermethylation of XAF1 in Hepatitis B Virus-Associated Hepatocellular Carcinoma Treated with Transplantation
Investigating the methylation status and expression level of XAF1 in human hepatitis B virus-associated hepatocellular carcinoma treated with liver transplantation (LT) found that expression level was an independent factor for predicting recurrence-free survival and protein level may serve as a potential biomarker for tumor recurrence after LT.
Snail1 is stabilized by O‐GlcNAc modification in hyperglycaemic condition
It is shown that by suppressing O‐phosphorylation‐mediated degradation, O‐GlcNAc at serine112 stabilizes Snail1 and thus increases its repressor function, which in turn attenuates E‐cadherin mRNA expression.
Overexpression of Long Non-coding RNA HOTAIR Predicts Tumor Recurrence in Hepatocellular Carcinoma Patients Following Liver Transplantation
The high expression level of HOTAIR in H CC could be a candidate biomarker for predicting tumor recurrence in HCC patients who have undergone liver transplant therapy and might be a potential therapeutic target.